News
AEZS
7.80
-2.99%
-0.24
Aeterna Zentaris Announces Share Consolidation
TipRanks · 4d ago
Aeterna Zentaris Initiates Major Share Consolidation
TipRanks · 4d ago
AETERNA ZENTARIS INC - SHARES EXPECTED TO COMMENCE TRADING ON TSX & ON NASDAQ ON A POST-CONSOLIDATION BASIS ON OR ABOUT OPENING OF TRADING ON MAY 3
Reuters · 4d ago
Aeterna Zentaris Announces Effective Date of Share Consolidation
Aeterna Zentaris Inc. Has filed articles of amendment to effect the previously announced share consolidation (or reverse stock split) of its issued and outstanding common shares. One post-Consolidation Common Share for every four pre-consolidated Common Shares.
Barchart · 4d ago
Weekly Report: what happened at AEZS last week (0422-0426)?
Weekly Report · 6d ago
Weekly Report: what happened at AEZS last week (0415-0419)?
Weekly Report · 04/22 11:02
Weekly Report: what happened at AEZS last week (0408-0412)?
Weekly Report · 04/15 10:55
Weekly Report: what happened at AEZS last week (0401-0405)?
Weekly Report · 04/08 10:59
Weekly Report: what happened at AEZS last week (0325-0329)?
Weekly Report · 04/01 10:57
Aeterna Zentaris Announces Merger Approval
TipRanks · 03/28 15:59
Aeterna Zentaris Announces Merger with Ceapro Inc.
Aeterna Zentaris Inc. Is set to merge with Ceapro Inc. The all-stock merger is expected to be completed in the second quarter of 2024. The move is anticipated to enhance their offerings in pharmaceutical and diagnostic products. TSE:AEZS has received final court approval for the merger.
TipRanks · 03/28 12:39
*AEterna Zentaris and Ceapro Anticipate Completing the Transaction in the 2Q of 2024 >AEZS
Dow Jones · 03/28 11:56
*Ceapro Receives Final Court Approval For Merger With Aeterna Zentaris AEZS
Dow Jones · 03/28 11:55
AEZS Stock Earnings: AEterna Zentaris Misses EPS for Q4 2023
AEterna Zentaris reported earnings per share of -$1.16. This was below the analyst estimate for EPS of -97 cents. The company reported revenue of $121,000. The stock was down 2.7% after the market closed on Wednesday.
Investorplace · 03/27 17:52
Aeterna Zentaris Financials Affirm Compliance
TipRanks · 03/27 15:30
Aeterna Zentaris Completes Key Trial Enrollment
TipRanks · 03/27 15:30
Aeterna Zentaris (AEZS) Reports Q4 Loss, Tops Revenue Estimates
NASDAQ · 03/27 13:25
AEterna Zentaris: Q4 Earnings Insights
AEterna Zentaris reported its Q4 earnings on March 27. The company missed estimates by $0.16. AEterna zentaris is expected to report earnings of $-1.16 per share. Last quarter the company missed by $1.24 and the share price dropped 6.0%.
Benzinga · 03/27 13:10
Aeterna Zentaris Completes Trial Enrollment, Plans Merger
TipRanks · 03/27 12:51
Aeterna Zentaris Inc: Report of foreign issuer
Press release · 03/27 12:28
More
Webull provides a variety of real-time AEZS stock news. You can receive the latest news about Aeterna Zentaris Inc through multiple platforms. This information may help you make smarter investment decisions.
About AEZS
Aeterna Zentaris Inc. is a Canada-based specialty biopharmaceutical company. The Company is developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products focused on areas of significant unmet medical need. The Company's lead product, macimorelin (Macrilen, Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also leveraging the clinical and compelling safety profile of macimorelin to develop it for the diagnosis of childhood-onset growth hormone deficiency (CGHD). The Company is engaged in the development of its therapeutic asset and has established a pre-clinical development pipeline to potentially address unmet medical needs across a number of indications, including neuromyelitis optica spectrum disorder (NMOSD), Parkinson's disease (PD), hypoparathyroidism and amyotrophic lateral sclerosis (ALS). Its therapeutic development pipeline includes AIM Biologicals, AEZS-150 and AEZS-130.